SCHEMBL28934278

SCHEMBL28934278

CC(C)(C)OC(=O)N1CCC[C@@H](Nc2nnc(Cl)c3c2CCCCC3)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
KMT2A Q03164 1/20 0.43
PIM1 P11309 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
USP30 Q70CQ3 3/20 0.42
BTK Q06187 2/20 0.41
EPHX1 P07099 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
TRPV1 Q8NER1 1/20 0.40
GLS O94925 1/20 0.40
EHMT2 Q96KQ7 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
PARP1 P09874 1/20 0.39
ANO1 Q5XXA6 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28934282 1.00 MEN1 (0.43) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL30101075 1.00 MEN1 (0.43) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL24574884 0.99 PIM1 (0.43) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL28934494 0.99 PIM1 (0.43) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL31057329 0.97 PIM1 (0.43) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL30157159 0.88 BTK (0.45) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL24575643 0.88 BTK (0.45) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL24575642 0.88 BTK (0.45) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL24575377 0.88 BTK (0.45) MEN1ALDH1A1MAPTKMT2APIM1
SCHEMBL31057366 0.88 BTK (0.45) MEN1ALDH1A1MAPTKMT2APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294542-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF TRANSTHERA SCIENCES (NANJING), INC. (CN) 2024-09-05 US disclosed
US-20240262806-A1 INHIBITORS OF NLRP3 PCT THERAPEUTICS, INC. (US) 2024-08-08 US disclosed
CN-118302417-A NLRP3 inhibitors PTC医疗公司 2024-07-05 CN disclosed
EP-4392414-A1 INHIBITORS OF NLRP3 PTC Therapeutics, Inc. (US) 2024-07-03 EP disclosed
WO-2023028534-A1 INHIBITORS OF NLRP3 PTC THERAPEUTICS, INC. (US) 2023-03-02 WO disclosed
CN-115433163-A NLRP3 inflammasome inhibitor and application thereof 药捷安康(南京)科技股份有限公司 2022-12-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294542-A1 NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF NLRP3, NLRP1, PYCARD MEN1 4031/4885ALDH1A1 2544/4885MAPT 57/4885
US-20240262806-A1 INHIBITORS OF NLRP3 NLRP3, NOD1, NLRP1 MEN1 4777/4885ALDH1A1 3173/4885MAPT 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.